RT Journal Article
SR Electronic
T1 Increased expression of WSX1 on alveolar lymphocytes (AL) in patients with early stage non-small cell lung cancer (NSCLC). Preliminary report
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2703
VO 44
IS Suppl 58
A1 Tomasz Wandtke
A1 Joanna Wielikdzien
A1 Cezary Rybacki
A1 Grzegorz Przybylski
A1 Joanna Golinska
A1 Blazej Przybyslawski
A1 Piotr Kopinski
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2703.abstract
AB Introduction: IL27 and its receptor - WSX1 - are essential for Th1 polarization in lungs. They are potentially useful in NSCLC therapy. IL27 is regarded to be exclusively produced by antigen presenting cells (APC), but we have previously reported IL27 production by AL. Little is known about WSX1 expression in lungs.Aim: Evaluation of WSX1 appearance in lower airways under physiological conditions and in early stages of NSCLC.Methods: WSX1 expression was determined by direct typing of bronchoalveolar lavage (BAL) cells, collected from patients with pulmonary sarcoidosis (PS, n=17, incl. 10 nonsmokers, NS), NSCLC (clinical stages I-IIa, n=12, incl. 5 NS) and controls (n=11, incl. 6 NS). IL27 expression was tested by ELISA in BAL supernatants.Results: NS patients demonstrated significantly higher WSX1 expression on AL as compared to resp. controls (PS: 6.5±2.3; NSCLC: 8.2±3.1 vs 3.8±1.1%; median±SEM, p<0.05). Similarly, increase of WSX1 on CD4+ and CD8+ cells was statistically significant in both patient NS groups. Healthy smokers revealed higher WSX1 expression as compared to NS controls (7.5±2.3 vs 3.8±1.1%, p<0.05). There was no difference of WSX1 expression between smoking subgroups. WSX1 results did not correlate with IL27 expression in lower airways.Conclusions: WSX1 seems to be a nonspecific AL activation marker, since its increase has been showed in PS and NSCLC. However, in opposite to PS, BAL cytoimmunological pattern in the NSCLC was similar to controls. T cell WSX1+ rate may serve as a sensitive marker of lung malignancy. Our results might confirm the role of IL27/WSX1 axis in anti-tumor immune response in NSCLC.